Published in Front Oncol on August 02, 2012
Rolling in the deep: therapeutic targeting of circulating tumor cells. Front Oncol (2012) 0.79
E- and p-selectins are essential for repopulation of chronic myelogenous and chronic eosinophilic leukemias in a scid mouse xenograft model. PLoS One (2013) 0.78
Serine protease inhibitor kunitz-type 2 is downregulated in myelodysplastic syndromes and modulates cell-cell adhesion. Stem Cells Dev (2014) 0.77
Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells. J Exp Clin Cancer Res (2017) 0.75
Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med (1997) 32.63
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature (1994) 21.59
Tumor growth need not be driven by rare cancer stem cells. Science (2007) 10.34
Cancer stem cells. N Engl J Med (2006) 9.63
In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature (2005) 6.60
Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice. Blood (2005) 6.16
Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med (2006) 5.92
CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell (2009) 5.30
CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell (2009) 5.22
Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol (2007) 5.21
Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature (2009) 4.99
Cancer stem cells: an evolving concept. Nat Rev Cancer (2012) 4.57
Isolation of a candidate human hematopoietic stem-cell population. Proc Natl Acad Sci U S A (1992) 4.28
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet (2012) 4.03
Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood (2008) 3.67
Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Science (2008) 3.39
Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med (2003) 3.33
The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia (2000) 3.32
Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood (2008) 3.19
Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell (2011) 3.12
Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice. J Clin Invest (2010) 2.96
Targeting HIF1α eliminates cancer stem cells in hematological malignancies. Cell Stem Cell (2011) 2.80
Aminoparthenolides as novel anti-leukemic agents: Discovery of the NF-kappaB inhibitor, DMAPT (LC-1). Bioorg Med Chem Lett (2009) 2.77
Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction. Blood (2010) 2.72
Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat Med (2006) 2.69
A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia. Blood (2012) 2.65
Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell (2009) 2.60
Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol (2011) 2.52
AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML. Blood (2005) 2.28
KDR receptor: a key marker defining hematopoietic stem cells. Science (1999) 2.13
Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood (2011) 2.13
An anti-PR1/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells. Blood (2011) 2.10
Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. Blood (2004) 2.05
Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood (2012) 2.03
Angiogenesis-dependent diseases. Semin Oncol (2001) 2.03
Is tumor growth sustained by rare cancer stem cells or dominant clones? Cancer Res (2008) 1.99
CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proc Natl Acad Sci U S A (2007) 1.99
High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res (2005) 1.94
mTOR activation induces tumor suppressors that inhibit leukemogenesis and deplete hematopoietic stem cells after Pten deletion. Cell Stem Cell (2010) 1.82
The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood (2007) 1.81
Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Sci Transl Med (2010) 1.78
Hedgehog signaling is dispensable for adult murine hematopoietic stem cell function and hematopoiesis. Cell Stem Cell (2009) 1.61
Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem (2002) 1.59
Right on target: eradicating leukemic stem cells. Trends Mol Med (2007) 1.49
Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells. Oncogene (2010) 1.45
Concise review: Emerging concepts in clinical targeting of cancer stem cells. Stem Cells (2011) 1.45
Most acute myeloid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34(+)/CD71(-)/HLA-DR-. Blood (1998) 1.44
CXCR4 expression and biologic activity in acute myeloid leukemia are dependent on oxygen partial pressure. Blood (2008) 1.44
Do reactive oxygen species play a role in myeloid leukemias? Blood (2011) 1.43
The vascular niche: home for normal and malignant hematopoietic stem cells. Leukemia (2011) 1.42
Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors. Clin Cancer Res (2011) 1.29
Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. Leukemia (2008) 1.27
Considerations for targeting malignant stem cells in leukemia. Cancer Control (2004) 1.20
Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia. Blood (2008) 1.20
The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell death. Blood (2007) 1.17
Targeting NF-kappaB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells. Blood (2004) 1.11
Delivery of apoptotic signal to rolling cancer cells: a novel biomimetic technique using immobilized TRAIL and E-selectin. Biotechnol Bioeng (2009) 1.11
Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. Blood (2012) 1.10
Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells. Br J Haematol (2010) 1.08
P-Selectin coated microtube for enrichment of CD34+ hematopoietic stem and progenitor cells from human bone marrow. Clin Chem (2007) 1.04
Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia. Haematologica (2009) 1.03
Analysis of factors that affect in vitro chemosensitivity of leukaemic stem and progenitor cells to gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukaemia. Leukemia (2009) 1.01
A small molecule screening strategy with validation on human leukemia stem cells uncovers the therapeutic efficacy of kinetin riboside. Blood (2011) 0.99
E-selectin liposomal and nanotube-targeted delivery of doxorubicin to circulating tumor cells. J Control Release (2012) 0.97
Circulating angiopoietin-2 is a strong prognostic factor in acute myeloid leukemia. Leukemia (2007) 0.95
High levels of the adhesion molecule CD44 on leukemic cells generate acute myeloid leukemia relapse after withdrawal of the initial transforming event. Leukemia (2010) 0.93
Leukemia-stimulated bone marrow endothelium promotes leukemia cell survival. Exp Hematol (2006) 0.92
Identification of T-lymphocytic leukemia-initiating stem cells residing in a small subset of patients with acute myeloid leukemic disease. Blood (2011) 0.92
Rakicidin A: a hypoxia-selective cytotoxin. Biol Pharm Bull (2007) 0.88
Role of Pten in leukemia stem cells. Oncotarget (2010) 0.87
The Hsp32 inhibitors SMA-ZnPP and PEG-ZnPP exert major growth-inhibitory effects on D34+/CD38+ and CD34+/CD38- AML progenitor cells. Curr Cancer Drug Targets (2012) 0.86
CD34(+)/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin. Haematologica (2011) 0.86
Heterogeneity of leukemia stem cell candidates at diagnosis of acute myeloid leukemia and their clinical significance. Exp Hematol (2011) 0.85
Targeting leukemia stem cells. Nat Biotechnol (2010) 0.85
Characterization of high-affinity peptides and their feasibility for use in nanotherapeutics targeting leukemia stem cells. Nanomedicine (2011) 0.83
Sonic hedgehog maintains survival and growth of chronic myeloid leukemia progenitor cells through β-catenin signaling. Exp Hematol (2012) 0.83
In vitro models. Stem Cells (2012) 0.82
Targeting integrin linked kinase and FMS-like tyrosine kinase-3 is cytotoxic to acute myeloid leukemia stem cells but spares normal progenitors. Leuk Res (2010) 0.82
Management of hepatic sinusoidal obstruction syndrome following treatment with gemtuzumab ozogamicin (Mylotarg). Clin Lymphoma (2002) 0.81
Antibody internalization after cell surface antigen binding is critical for immunotoxin development. Bioconjug Chem (2009) 0.81
Novel combination treatments targeting chronic myeloid leukemia stem cells. Clin Lymphoma Myeloma Leuk (2011) 0.79
Hypothesis: myeloid-restricted hematopoietic stem cells with self-renewal capacity may be the transformation site in acute myeloid leukemia. Leuk Res (2005) 0.79
Detection and clinical significance of human acute myeloid leukaemia progenitors capable of long-term proliferation in vitro. Br J Haematol (2001) 0.79
Sensitising leukemic cells by targeting microenvironment. Leuk Lymphoma (2009) 0.77
Monoclonal antibodies and immunoconjugates in acute myeloid leukemia. Best Pract Res Clin Haematol (2006) 0.76